Cronotaraxis como síntoma guía de un infarto talámico medial / Chronotaraxis as a harbinger of medial thalamic infarction

La cronotaraxis es una afectación de la percepción de la secuencia temporal. Esta alteración de la temporalidad se ha descrito asociada de forma característica a la afectación talámica, concretamente al núcleo dorsomediano. Casos clínicos. Presentamos los casos clínicos de dos pacientes con ictus isquémicos agudos de localización en dicho territorio, con una clínica basada en este síntoma y cuyo reconocimiento resultó esencial en el abordaje terapéutico. Tanto en el primero como en el segundo caso se describe cómo la percepción de la temporalidad fue esencial para el diagnóstico de la patología isquémica de ambos pacientes. Discusión. El conocimiento y la divulgación de esta asociación pueden resultar fundamentales en el manejo de los pacientes con alteraciones talámicas. Esto se debe a la posibilidad que surge de influir y modificar el abordaje inicial, puesto que el reconocimiento de un síntoma específico, como es la cronotaraxis, puede evitar la extensión del daño talámico, y prevenir de esta manera las secuelas, sobre todo cognitivas, que ocasiona a largo plazo.(AU)

Introduction: Chronotaraxis is an impairment of the perception of the sequencing of time. This alteration of temporality has been described as being characteristically associated with thalamic involvement, specifically in the dorsomedial nucleus. Case reports: We report the clinical cases of two patients with acute ischaemic strokes located in said territory, with a clinical presentation based on this symptom and the recognition of which was essential in the therapeutic approach. In the first and second cases, it is described how the perception of temporality was essential for the diagnosis of the ischaemic condition in both patients. Discussion: Awareness and dissemination of this association may be vital in the management of patients with thalamic disorders. This is due to the possibility of influencing and modifying the initial approach, since the recognition of a specific symptom, such as chronotaraxis, can prevent the spread of thalamic damage, in addition to the long-term sequelae that it causes, especially those of a cognitive nature.(AU)

[Chronotaraxis as a harbinger of medial thalamic infarction]. / Cronotaraxis como síntoma guía de un infarto talámico medial.

INTRODUCTION: Chronotaraxis is an impairment of the perception of the sequencing of time. This alteration of temporality has been described as being characteristically associated with thalamic involvement, specifically in the dorsomedial nucleus. CASE REPORTS: We report the clinical cases of two patients with acute ischaemic strokes located in said territory, with a clinical presentation based on this symptom and the recognition of which was essential in the therapeutic approach. In the first and second cases, it is described how the perception of temporality was essential for the diagnosis of the ischaemic condition in both patients. DISCUSSION: Awareness and dissemination of this association may be vital in the management of patients with thalamic disorders. This is due to the possibility of influencing and modifying the initial approach, since the recognition of a specific symptom, such as chronotaraxis, can prevent the spread of thalamic damage, in addition to the long-term sequelae that it causes, especially those of a cognitive nature.

TITLE: Cronotaraxis como síntoma guía de un infarto talámico medial.Introducción. La cronotaraxis es una afectación de la percepción de la secuencia temporal. Esta alteración de la temporalidad se ha descrito asociada de forma característica a la afectación talámica, concretamente al núcleo dorsomediano. Casos clínicos. Presentamos los casos clínicos de dos pacientes con ictus isquémicos agudos de localización en dicho territorio, con una clínica basada en este síntoma y cuyo reconocimiento resultó esencial en el abordaje terapéutico. Tanto en el primero como en el segundo caso se describe cómo la percepción de la temporalidad fue esencial para el diagnóstico de la patología isquémica de ambos pacientes. Discusión. El conocimiento y la divulgación de esta asociación pueden resultar fundamentales en el manejo de los pacientes con alteraciones talámicas. Esto se debe a la posibilidad que surge de influir y modificar el abordaje inicial, puesto que el reconocimiento de un síntoma específico, como es la cronotaraxis, puede evitar la extensión del daño talámico, y prevenir de esta manera las secuelas, sobre todo cognitivas, que ocasiona a largo plazo.

Identificando puntos de mejoría en el manejo de la epilepsia en países en vías de desarrollo: experiencia de neurocooperación en Camerún / Identifying areas for improvement in epilepsy management in developing countries: An experience of neurocooperation in Cameroon

INTRODUCCIÓN: La epilepsia es una enfermedad prevalente en países en vías de desarrollo debido al mayor número de causas que pueden producirla, al menos duplicándose tanto incidencia como prevalencia en comparación con nuestro medio. Además, existe una gran estigmatización y los medios para su manejo son limitados. MATERIAL Y MÉTODOS: Estudio observacional descriptivo mediante la realización de un cuestionario a profesionales sanitarios de 3 hospitales de Camerún, interrogando sobre factores relacionados con el manejo de la epilepsia, en diciembre de 2016. Se presentan los datos como media o porcentaje. RESULTADOS: Participaron 38 profesionales sanitarios, de los cuales el 42,1% eran mujeres, con una edad media de 40,1 años (rango 22-62). Respecto a la causa de la enfermedad un 68,4% la considera psiquiátrica, 34,2% degenerativa, 28,9% hereditaria y 21,1% secundaria a una infección. En cuanto al manejo un 23,7% consideraba suficiente la anamnesis para llegar al diagnóstico. Solo un 60,5% consideraba la historia importante en el diagnóstico, 52,6% consideraba necesario un EEG, un 28,9% creía importantes las pruebas de laboratorio y un 13,2% la neuroimagen. Durante el embarazo solo un 36,8% considera importante asociar ácido fólico, solo el 65,8% cree que hay que mantener el tratamiento y solo un 39,5% creía recomendable la lactancia. Acerca del conocimiento de antiepilépticos, el número medio de fármacos conocido era de 2, siendo el más conocido el fenobarbital (81,6%) seguido de carbamacepina (55,3%) y ácido valproico (28,9%). CONCLUSIONES: La educación y la mejor información sobre la enfermedad, su diagnóstico y las opciones de manejo son necesarias en los profesionales sanitarios para optimizar el manejo y con ello la calidad de vida de los pacientes

INTRODUCTION: Epilepsy is especially prevalent in developing countries: incidence and prevalence rates are at least twice as high as in our setting. Epilepsy is also highly stigmatised, and few resources are available for its management. MATERIAL AND METHODS: We performed a descriptive observational study in December 2016, distributing a questionnaire on epilepsy management to healthcare professionals from 3 different hospitals in Cameroon. Data are presented as means or percentages. RESULTS: Thirty-eight healthcare providers participated in the survey; 42.1% were female and mean age was 40.1 years (range, 22-62). Regarding the causes of epilepsy, 68.4% considered it a psychiatric condition, 34.2% a degenerative disease, 28.9% a hereditary condition, and 21.1% secondary to infection. In terms of management, 23.7% considered that thorough clinical history is sufficient to establish a diagnosis. Only 60.5% considered the clinical interview to be important for diagnosis, 52.6% considered EEG to be necessary, and 28.9% considered laboratory analyses to be important. Only 13.2% mentioned neuroimaging. In the treatment of pregnant women, 36.8% recommended folic acid supplementation, 65.8% believed antiepileptic treatment should be maintained, and only 39.5% recommended breastfeeding. Concerning treatment, the participants knew a mean of 2 antiepileptic drugs: phenobarbital was the best known (81.6%), followed by carbamazepine (55.3%) and valproic acid (28.9%). CONCLUSIONS: There is a need among healthcare professionals for education and information on the disease, its diagnosis, and management options, in order to optimise management and consequently improve patients' quality of life

Identifying areas for improvement in epilepsy management in developing countries: An experience of neurocooperation in Cameroon. / Identificando puntos de mejoría en el manejo de la epilepsia en países en vías de desarrollo: experiencia de neurocooperación en Camerún.

INTRODUCTION: Epilepsy is especially prevalent in developing countries: incidence and prevalence rates are at least twice as high as in our setting. Epilepsy is also highly stigmatised, and few resources are available for its management. MATERIAL AND METHODS: We performed a descriptive observational study in December 2016, distributing a questionnaire on epilepsy management to healthcare professionals from 3 different hospitals in Cameroon. Data are presented as means or percentages. RESULTS: Thirty-eight healthcare providers participated in the survey; 42.1% were female and mean age was 40.1 years (range, 22-62). Regarding the causes of epilepsy, 68.4% considered it a psychiatric condition, 34.2% a degenerative disease, 28.9% a hereditary condition, and 21.1% secondary to infection. In terms of management, 23.7% considered that thorough clinical history is sufficient to establish a diagnosis. Only 60.5% considered the clinical interview to be important for diagnosis, 52.6% considered EEG to be necessary, and 28.9% considered laboratory analyses to be important. Only 13.2% mentioned neuroimaging. In the treatment of pregnant women, 36.8% recommended folic acid supplementation, 65.8% believed antiepileptic treatment should be maintained, and only 39.5% recommended breastfeeding. Concerning treatment, the participants knew a mean of 2 antiepileptic drugs: phenobarbital was the best known (81.6%), followed by carbamazepine (55.3%) and valproic acid (28.9%). CONCLUSIONS: There is a need among healthcare professionals for education and information on the disease, its diagnosis, and management options, in order to optimise management and consequently improve patients' quality of life.

Encefalopatía con lesión reversible del cuerpo calloso: una entidad poco conocida con pronóstico favorable / Mild encephalitis/encephalopathy with reversible splenial lesion: A little-known entity with favourable prognosis

No disponible

Should we expect neurological symptoms in the SARS-CoV-2 epidemic? / ¿Es esperable que haya cuadros neurológicos por la pandemia por SARS-CoV-2?

INTRODUCTION: There is growing evidence that SARS-CoV-2 can gain access to the central nervous system (CNS). We revise the literature on coronavirus infection of the CNS associated with neurological diseases. DEVELOPMENT: Neurological symptoms were rarely reported in the SARS-CoV and MERS-CoV epidemics, although isolated cases were described. There are also reports of cases of neurological symptoms associated with CoV-OC43 and CoV-229E infection. The presence of neurological lesions, especially demyelinating lesions in the mouse hepatitis virus model, may explain the mechanisms by which coronaviruses enter the CNS, particularly those related with the immune response. This may explain the presence of coronavirus in patients with multiple sclerosis. We review the specific characteristics of SARS-CoV-2 and address the question of whether the high number of cases may be associated with greater CNS involvement. CONCLUSION: Although neurological symptoms are not frequent in coronavirus epidemics, the high number of patients with SARS-CoV-2 infection may explain the presence of the virus in the CNS and increase the likelihood of early- or delayed-onset neurological symptoms. Follow-up of patients affected by the SARS-CoV-2 epidemic should include careful assessment of the CNS.

¿Es esperable que haya cuadros neurológicos por la pandemia por SARS-CoV-2? / Should we expect neurological symptoms in the SARS-CoV-2 epidemic?

INTRODUCCIÓN: Diversas evidencias sugieren que el SARS-CoV-2 puede penetrar en el sistema nervioso central (SNC). Los autores revisan los datos de la literatura sobre los hallazgos de coronavirus en el SNC asociado a enfermedades neurológicas. DESARROLLO: En las distintas epidemias con SARS-CoV y MERS-CoV la presencia de cuadros neurológicos es baja, pero se describen cuadros aislados de pacientes. También existen casos asociados a OC43-CoV y 229E-CoV. La existencia de lesiones neurológicas, especialmente desmielinizantes en el modelo MHV-CoV pueden explicar mecanismos de penetración de los CoV en el SNC y especialmente aquellos relacionados con la respuesta inmune, que puede justificar la existencia de CoV en pacientes con esclerosis múltiple. Los autores revisan aspectos diferenciales de SARS-CoV-2 y se plantean si debido al alto número de infectados, el virus puede afectar de forma mayor al SNC. CONCLUSIÓN: Aunque la presencia de síntomas neurológicos en las epidemias de CoV es baja, la mayor frecuencia de infectados por SARS-CoV-2 podría justificar el paso del virus y la posibilidad de clínica neurológica precoz o tardía con mayor incidencia. El seguimiento de los pacientes de la epidemia debe atender con cuidado a la evaluación del SNC

INTRODUCTION: There is growing evidence that SARS-CoV-2 can gain access to the central nervous system (CNS). We revise the literature on coronavirus infection of the CNS associated with neurological diseases. DEVELOPMENT: Neurological symptoms were rarely reported in the SARS-CoV and MERS-CoV epidemics, although isolated cases were described. There are also reports of cases of neurological symptoms associated with CoV-OC43 and CoV-229E infection. The presence of neurological lesions, especially demyelinating lesions in the mouse hepatitis virus model, may explain the mechanisms by which coronaviruses enter the CNS, particularly those related with the immune response. This may explain the presence of coronavirus in patients with multiple sclerosis. We review the specific characteristics of SARS-CoV-2 and address the question of whether the high number of cases may be associated with greater CNS involvement. CONCLUSIÓN: Although neurological symptoms are not frequent in coronavirus epidemics, the high number of patients with SARS-CoV-2 infection may explain the presence of the virus in the CNS and increase the likelihood of early- or delayed-onset neurological symptoms. Follow-up of patients affected by the SARS-CoV-2 epidemic should include careful assessment of the CNS